Filing Flows › bioAffinity Technologies (BIAF) › Q3 2026 › vs Q3 2025
bioAffinity Technologies (BIAF) Q3 2026 vs Q3 2025 (year over year)
bioAffinity Technologies's revenue fell $376K (-26%) from $1.4M in Q3 2025 to $1.1M in Q3 2026. The biggest changes: Health Care, Patient Service −$309K (-26%); Histology Service Fees −$66K (-26%); Medical Director Fees −$67 (-0.4%).
bioAffinity Technologies, Q3 2026: revenue $1.1M (-26% year over year), operating margin -328.0%, net loss $5.3M, operating cash flow −$3.9M. The chart draws each line against Q3 2025, the increases inside each band.
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Health Care, Patient Service | $863K | $1.2M | −$309K | -26% |
| Histology Service Fees | $190K | $256K | −$66K | -26% |
| Medical Director Fees | $17K | $17K | −$67 | -0.4% |
| Revenue | $1.1M | $1.4M | −$376K | -26% |
| Net loss | $5.3M | $5.1M | $226K | +4% |
| Costs & expenses | $6.3M | $6.5M | −$150K | -2% |
| Operating costs | $4.6M | $3.7M | $842K | +23% |
| Interest & other, net | $1.8M | $2.8M | −$989K | -36% |
| Research & development | $389K | $331K | $59K | +18% |
| SG&A | $2.8M | $2.2M | $550K | +25% |
| Other operating costs | $1.4M | $1.2M | $233K | +19% |
| Operating cash sources | $5.3M | $5.1M | $226K | +4% |
| Depreciation & amortization | $67K | $113K | −$47K | -41% |
| Share-based compensation | $139K | $67K | $72K | +107% |
| Working capital & other | $1.2M | $2.4M | −$1.2M | -50% |
| Cash used in operations | $3.9M | $2.5M | $1.4M | +56% |
| Net loss absorbed | $5.3M | $5.1M | $226K | +4% |
Questions
How much did bioAffinity Technologies's revenue grow year over year in Q3 2026?
bioAffinity Technologies's revenue fell $376K (-26%) from $1.4M in Q3 2025 to $1.1M in Q3 2026.
What drove bioAffinity Technologies's revenue change in Q3 2026?
Health Care, Patient Service −$309K (-26%); Histology Service Fees −$66K (-26%); Medical Director Fees −$67 (-0.4%).